Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes

Abeer Madbouly; Tao Wang; Michael Haagenson; Vanja Paunic; Cynthia Vierra-Green; Katharina Fleischhauer; Katharine C. Hsu; Michael R. Verneris; Navneet S. Majhail; Stephanie J. Lee; Stephen R. Spellman; Martin Maiers

doi:10.1016/j.bbmt.2017.02.019

Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes

Abeer Madbouly, Tao Wang, Michael Haagenson, Vanja Paunic, Cynthia Vierra-Green, Katharina Fleischhauer, Katharine C. Hsu, Michael R. Verneris, Navneet S. Majhail, Stephanie J. Lee, Stephen R. Spellman, Martin Maiers

Pediatric Blood & Marrow Transplant & Cellular Therapy

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Disparities in survival after allogeneic hematopoietic cell transplantation have been reported for some race and ethnic groups, despite comparable HLA matching. Individuals' ethnic and race groups, as reported through self-identification, can change over time because of multiple sociological factors. We studied the effect of 2 measures of genetic similarity in 1378 recipients who underwent myeloablative first allogeneic hematopoietic cell transplantation between 1995 and 2011 and their unrelated 10 of 10 HLA-A, -B, -C, -DRB1, and-DQB1- matched donors. The studied factors were as follows (1) donor and recipient genetic ancestral admixture and (2) pairwise donor/recipient genetic distance. Increased African genetic admixture for either transplant recipients or donors was associated with increased risk of overall mortality (hazard ratio [HR], 2.26; P = .005 and HR, 3.09; P = .0002, respectively) and transplant-related mortality (HR, 3.3; P = .0003 and HR, 3.86; P = .0001, respectively) and decreased disease-free survival (HR, 1.9; P = .02 and HR, 2.46; P = .002 respectively). The observed effect, albeit statistically significant, was relevant to a small subset of the studied population and was notably correlated with self-reported African-American race. We were not able to control for other nongenetic factors, such as access to health care or other socioeconomic factors; however, the results suggest the influence of a genetic driver. Our findings confirm what has been previously reported for African-American recipients and show similar results for donors. No significant association was found with donor/recipient genetic distance.

Original language	English (US)
Pages (from-to)	1029-1037
Number of pages	9
Journal	Biology of Blood and Marrow Transplantation
Volume	23
Issue number	6
DOIs	https://doi.org/10.1016/j.bbmt.2017.02.019
State	Published - Jun 2017

Bibliographical note

Funding Information:
We would like to acknowledge Mark Albrecht for his valuable input on some analysis aspects and Heather Severance for helping with the submission process. This work was supported by the Office of Naval Research grant N00014-11-1-0339. The CIBMTR is supported by Public Health Service grant/cooperative agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); 2 grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Alexion; *Amgen Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics, Inc.; Be The Match Foundation; *Bluebird Bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Jeff Gordon Children's Foundation; Leukemia and Lymphoma Society; Medac, GmbH; MedImmune; Medical College of Wisconsin; *Merck & Co., Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co., Ltd.—Japan; PCORI; Perkin Elmer, Inc.; Pfizer Inc.; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA), or any other agency of the US government.

Funding Information:
We would like to acknowledge Mark Albrecht for his valuable input on some analysis aspects and Heather Severance for helping with the submission process. This work was supported by the Office of Naval Research grant N00014-11-1-0339. The CIBMTR is supported by Public Health Service grant/cooperative agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); 2 grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Alexion; *Amgen Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics, Inc.; Be The Match Foundation; *Bluebird Bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Jeff Gordon Children's Foundation; Leukemia and Lymphoma Society; Medac, GmbH; MedImmune; Medical College of Wisconsin; *Merck & Co., Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co., Ltd.?Japan; PCORI; Perkin Elmer, Inc.; Pfizer Inc.; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA), or any other agency of the US government.

Publisher Copyright:
© 2017 The American Society for Blood and Marrow Transplantation

Keywords

African-American race
Ancestry informative markers
Genetic admixture
Genetic ancestry
Hematopoietic stem cell transplantation
Race and ethnicity

Publisher link

10.1016/j.bbmt.2017.02.019

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541944

Find It

Find It at U of M Libraries

Cite this

Madbouly, A., Wang, T., Haagenson, M., Paunic, V., Vierra-Green, C., Fleischhauer, K., Hsu, K. C., Verneris, M. R., Majhail, N. S., Lee, S. J., Spellman, S. R., & Maiers, M. (2017). Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes. Biology of Blood and Marrow Transplantation, 23(6), 1029-1037. https://doi.org/10.1016/j.bbmt.2017.02.019

Madbouly, A, Wang, T, Haagenson, M, Paunic, V, Vierra-Green, C, Fleischhauer, K, Hsu, KC, Verneris, MR, Majhail, NS, Lee, SJ, Spellman, SR & Maiers, M 2017, 'Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes', Biology of Blood and Marrow Transplantation, vol. 23, no. 6, pp. 1029-1037. https://doi.org/10.1016/j.bbmt.2017.02.019

@article{bf700532571b406f85c89b9a56e4a8ec,

title = "Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes",

abstract = "Disparities in survival after allogeneic hematopoietic cell transplantation have been reported for some race and ethnic groups, despite comparable HLA matching. Individuals' ethnic and race groups, as reported through self-identification, can change over time because of multiple sociological factors. We studied the effect of 2 measures of genetic similarity in 1378 recipients who underwent myeloablative first allogeneic hematopoietic cell transplantation between 1995 and 2011 and their unrelated 10 of 10 HLA-A, -B, -C, -DRB1, and-DQB1- matched donors. The studied factors were as follows (1) donor and recipient genetic ancestral admixture and (2) pairwise donor/recipient genetic distance. Increased African genetic admixture for either transplant recipients or donors was associated with increased risk of overall mortality (hazard ratio [HR], 2.26; P = .005 and HR, 3.09; P = .0002, respectively) and transplant-related mortality (HR, 3.3; P = .0003 and HR, 3.86; P = .0001, respectively) and decreased disease-free survival (HR, 1.9; P = .02 and HR, 2.46; P = .002 respectively). The observed effect, albeit statistically significant, was relevant to a small subset of the studied population and was notably correlated with self-reported African-American race. We were not able to control for other nongenetic factors, such as access to health care or other socioeconomic factors; however, the results suggest the influence of a genetic driver. Our findings confirm what has been previously reported for African-American recipients and show similar results for donors. No significant association was found with donor/recipient genetic distance.",

keywords = "African-American race, Ancestry informative markers, Genetic admixture, Genetic ancestry, Hematopoietic stem cell transplantation, Race and ethnicity",

author = "Abeer Madbouly and Tao Wang and Michael Haagenson and Vanja Paunic and Cynthia Vierra-Green and Katharina Fleischhauer and Hsu, {Katharine C.} and Verneris, {Michael R.} and Majhail, {Navneet S.} and Lee, {Stephanie J.} and Spellman, {Stephen R.} and Martin Maiers",

note = "Funding Information: We would like to acknowledge Mark Albrecht for his valuable input on some analysis aspects and Heather Severance for helping with the submission process. This work was supported by the Office of Naval Research grant N00014-11-1-0339. The CIBMTR is supported by Public Health Service grant/cooperative agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); 2 grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Alexion; *Amgen Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics, Inc.; Be The Match Foundation; *Bluebird Bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Jeff Gordon Children's Foundation; Leukemia and Lymphoma Society; Medac, GmbH; MedImmune; Medical College of Wisconsin; *Merck & Co., Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co., Ltd.—Japan; PCORI; Perkin Elmer, Inc.; Pfizer Inc.; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA), or any other agency of the US government. Funding Information: We would like to acknowledge Mark Albrecht for his valuable input on some analysis aspects and Heather Severance for helping with the submission process. This work was supported by the Office of Naval Research grant N00014-11-1-0339. The CIBMTR is supported by Public Health Service grant/cooperative agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); 2 grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Alexion; *Amgen Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics, Inc.; Be The Match Foundation; *Bluebird Bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Jeff Gordon Children's Foundation; Leukemia and Lymphoma Society; Medac, GmbH; MedImmune; Medical College of Wisconsin; *Merck & Co., Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co., Ltd.?Japan; PCORI; Perkin Elmer, Inc.; Pfizer Inc.; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA), or any other agency of the US government. Publisher Copyright: {\textcopyright} 2017 The American Society for Blood and Marrow Transplantation",

year = "2017",

month = jun,

doi = "10.1016/j.bbmt.2017.02.019",

language = "English (US)",

volume = "23",

pages = "1029--1037",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes

AU - Madbouly, Abeer

AU - Wang, Tao

AU - Haagenson, Michael

AU - Paunic, Vanja

AU - Vierra-Green, Cynthia

AU - Fleischhauer, Katharina

AU - Hsu, Katharine C.

AU - Verneris, Michael R.

AU - Majhail, Navneet S.

AU - Lee, Stephanie J.

AU - Spellman, Stephen R.

AU - Maiers, Martin

N1 - Funding Information: We would like to acknowledge Mark Albrecht for his valuable input on some analysis aspects and Heather Severance for helping with the submission process. This work was supported by the Office of Naval Research grant N00014-11-1-0339. The CIBMTR is supported by Public Health Service grant/cooperative agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); 2 grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Alexion; *Amgen Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics, Inc.; Be The Match Foundation; *Bluebird Bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Jeff Gordon Children's Foundation; Leukemia and Lymphoma Society; Medac, GmbH; MedImmune; Medical College of Wisconsin; *Merck & Co., Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co., Ltd.—Japan; PCORI; Perkin Elmer, Inc.; Pfizer Inc.; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA), or any other agency of the US government. Funding Information: We would like to acknowledge Mark Albrecht for his valuable input on some analysis aspects and Heather Severance for helping with the submission process. This work was supported by the Office of Naval Research grant N00014-11-1-0339. The CIBMTR is supported by Public Health Service grant/cooperative agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a grant/cooperative agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); 2 grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; Alexion; *Amgen Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics, Inc.; Be The Match Foundation; *Bluebird Bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cellular Dynamics International, Inc.; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Genentech, Inc.; Genzyme Corporation; Gilead Sciences, Inc.; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics; Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Jeff Gordon Children's Foundation; Leukemia and Lymphoma Society; Medac, GmbH; MedImmune; Medical College of Wisconsin; *Merck & Co., Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; *Miltenyi Biotec; National Marrow Donor Program; Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Co., Ltd.?Japan; PCORI; Perkin Elmer, Inc.; Pfizer Inc.; *Sanofi US; *Seattle Genetics; *Spectrum Pharmaceuticals; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; University of Minnesota; and *WellPoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA), or any other agency of the US government. Publisher Copyright: © 2017 The American Society for Blood and Marrow Transplantation

PY - 2017/6

Y1 - 2017/6

N2 - Disparities in survival after allogeneic hematopoietic cell transplantation have been reported for some race and ethnic groups, despite comparable HLA matching. Individuals' ethnic and race groups, as reported through self-identification, can change over time because of multiple sociological factors. We studied the effect of 2 measures of genetic similarity in 1378 recipients who underwent myeloablative first allogeneic hematopoietic cell transplantation between 1995 and 2011 and their unrelated 10 of 10 HLA-A, -B, -C, -DRB1, and-DQB1- matched donors. The studied factors were as follows (1) donor and recipient genetic ancestral admixture and (2) pairwise donor/recipient genetic distance. Increased African genetic admixture for either transplant recipients or donors was associated with increased risk of overall mortality (hazard ratio [HR], 2.26; P = .005 and HR, 3.09; P = .0002, respectively) and transplant-related mortality (HR, 3.3; P = .0003 and HR, 3.86; P = .0001, respectively) and decreased disease-free survival (HR, 1.9; P = .02 and HR, 2.46; P = .002 respectively). The observed effect, albeit statistically significant, was relevant to a small subset of the studied population and was notably correlated with self-reported African-American race. We were not able to control for other nongenetic factors, such as access to health care or other socioeconomic factors; however, the results suggest the influence of a genetic driver. Our findings confirm what has been previously reported for African-American recipients and show similar results for donors. No significant association was found with donor/recipient genetic distance.

AB - Disparities in survival after allogeneic hematopoietic cell transplantation have been reported for some race and ethnic groups, despite comparable HLA matching. Individuals' ethnic and race groups, as reported through self-identification, can change over time because of multiple sociological factors. We studied the effect of 2 measures of genetic similarity in 1378 recipients who underwent myeloablative first allogeneic hematopoietic cell transplantation between 1995 and 2011 and their unrelated 10 of 10 HLA-A, -B, -C, -DRB1, and-DQB1- matched donors. The studied factors were as follows (1) donor and recipient genetic ancestral admixture and (2) pairwise donor/recipient genetic distance. Increased African genetic admixture for either transplant recipients or donors was associated with increased risk of overall mortality (hazard ratio [HR], 2.26; P = .005 and HR, 3.09; P = .0002, respectively) and transplant-related mortality (HR, 3.3; P = .0003 and HR, 3.86; P = .0001, respectively) and decreased disease-free survival (HR, 1.9; P = .02 and HR, 2.46; P = .002 respectively). The observed effect, albeit statistically significant, was relevant to a small subset of the studied population and was notably correlated with self-reported African-American race. We were not able to control for other nongenetic factors, such as access to health care or other socioeconomic factors; however, the results suggest the influence of a genetic driver. Our findings confirm what has been previously reported for African-American recipients and show similar results for donors. No significant association was found with donor/recipient genetic distance.

KW - African-American race

KW - Ancestry informative markers

KW - Genetic admixture

KW - Genetic ancestry

KW - Hematopoietic stem cell transplantation

KW - Race and ethnicity

UR - http://www.scopus.com/inward/record.url?scp=85017554048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017554048&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2017.02.019

DO - 10.1016/j.bbmt.2017.02.019

M3 - Article

C2 - 28263917

AN - SCOPUS:85017554048

SN - 1083-8791

VL - 23

SP - 1029

EP - 1037

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 6

ER -

Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this